# Pharmacokinetic Study of Buparlisib in Subjects With Renal Impairment.

> **NCT02048787** · PHASE1 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 19 (actual)

## Conditions studied

- Renal Impairment

## Interventions

- **DRUG:** Buparlisib

## Key facts

- **NCT ID:** NCT02048787
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-03
- **Primary completion:** 2015-03
- **Final completion:** 2015-03
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2020-12-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02048787

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02048787, "Pharmacokinetic Study of Buparlisib in Subjects With Renal Impairment.". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02048787. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*